May 25, 2011 (Washington, DC) — OnabotulinumtoxinA significantly decreases episodes of urinary incontinence (UI) secondary to neurogenic detrusor overactivity (NDO) in patients with multiple ...

Among the subgroup, 25.5% discontinued treatment; more patients discontinued the CGRP monoclonal antibody vs. onabotulinumtoxinA (24.2% vs. 3%), according to the researchers.

AbbVie (NYSE: ABBV) announced today that atogepant and onabotulinumtoxinA have received strong recommendations in the newly updated CHS Migraine Prevention Guideline: atogepant is strongly ...

The overall range of doses of onabotulinumtoxinA injected into lower-limb muscles varied greatly, from 10–400 U. Mean doses ranged from 30.0 U in the vastus medialis to 186.9 U in the rectus ...

Cluster headache attacks were significantly reduced in frequency after administration of onabotulinumtoxinA towards the sphenopalatine ganglion, according to a study in Cephalalgia.Researchers in ...

OnabotulinumtoxinA treatment is safe and effective for long-term treatment of overactive bladder syndrome, according to a study published in the September issue of The Journal of Urology.

BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before Published Nov 1, 2023 8:45am EDT ...

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands ...

Compared with best supportive care (BSC), onabotulinumtoxinA was found to be the most cost-effective treatment for patients with refractory overactive bladder (OAB) from a US payer perspective ...

BOTOX® (onabotulinumtoxinA) Receives U.S. Food and Drug Administration Approval for the Treatment of Overactive Bladder for Adults Who Have an Inadequate Response to or Are Intolerant of An ...